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cancers.Optimized NGS panel and data analysis
enable high sensitivity of detecting
colon and lung cancer associated
mutations from plasmaLina Ma, Feng Zhang, Qing Xu, Xiannian Tang,
Mao Mao WuXi AppTec, Shanghai, ChinaTracking tumor-associated mutation in plasma can serve
as biomarkers to facilitate cancer diagnosis and provide
guidance for target therapy. The intrinsic low abundance
and short fragments of circulating cell-free tumor DNA
(cfDNA) make the mutation detection from plasma a
challenging task. Next Generation Sequencing (NGS) al-
lows high throughput mutation analysis of cancer genes
by massively parallel sequencing. Ion Ampliseq panel is
able to construct the library with as little as 10ng DNA,
suitable for the limited amount from cfDNA. However,
the commercial Ampliseq panel together with the TVC
(Ion Torrent variant caller software) analysis was mainly
designed for mutation detection from FFPE samples. The
sensitivity is not good enough for cfDNA mutation
detection based on our assessment.
Here we have established a strategy to detect so-
matic mutations of colon and lung cancer with plasma
based on AmpliSeq Ion Torrent System. Firstly, a colon
and lung panel was designed for small amplicons (less
than 140bp), so as to better capture small cfDNA
fragments as effective templates in multiplex PCR. The
ampliﬁcation test shows that our panel produced
amplicons with a good uniformity when applied to
cfDNA. Secondly, background noise analysis has shown
the noise unevenly distributed along the genome and
error hotspots repeatedly showed up among different
samples. Based on the features of background noise, we
have developed a new algorithm to distinguish low
level mutations from sequencing errors, which makes
use of sequencing data from healthy individuals as
reference to estimate the sequencing error proﬁle. A
reliability of the mutant allele at each position was
evaluated by statistical test of background noise versus
signal. To evaluate the detection limit of our approach,
a cell line mix which contains several mutations at
different level of mutations was examined. Digital
droplet PCR (ddPCR) assay was used to conﬁrm the
allele frequency of each mutation. This analysis dem-
onstrates that our approach is able to call mutations at
a fractional abundance of 0.15-0.3%, depending on the
genomic positions. The allele frequency from
sequencing result correlates well with ddPCR result(R2¼0.90). Moreover, the analytical speciﬁcity is higher
than 99% with such detection limit.
To test the clinical performance of our method, cfDNA
from non-small cell lung cancer (NSCLC) patients was
used. With 10ng cfDNA, this method is able to call mu-
tation as low as 0.5%, the lowest clinical sample tested,
while with the commercial kit and variant analysis
software, it only calls at 5%. The detection limit of our
approach for clinical cfDNA sample will be determined
with more tests.
Ion Torrent PGM has been widely used in clinical
environment, because of its cost and time effective way
compatible with clinical practice. In this proof-of-concept
study, our strategy comprised of an optimized panel
suitable for cfDNA and a novel variant calling algorithm
signiﬁcantly improves the detection limit of the PGM
platform, making it possible to detect low abundant
mutations from plasma. We envision this approach could
have utility for patient stratiﬁcation, monitoring
response to therapies and detection of relapse.Constitution of ALK fusion variants in
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Introduction: The purpose of the study is to investigate
the constitution of anaplastic lymphoma kinase (ALK)
fusion variants in East Asian lung adenocarcinoma
(LUAC) patients and to provide instructional data for the
variants that should be included in the companion
diagnostic assay to screen for ALK positive patients.
Methods: From June 2014 to August 2015, 158 ALK
fusion positive formalin-ﬁxed, parafﬁn-embedded
(FFPE) samples were identiﬁed, including 3 patient-
derived xenograft (PDX) tissues and 155 resected or ﬁne
needle aspiration (FNA) tissues, all derived from Korean
or Chinese patients. Either puriﬁed RNA or crude tissue
lysate from the 158 FFPE samples were analyzed by
NanoString nCounter Elements assay with a multiplexed
probe mix in a single tube targeting ALK fusion tran-
scripts including 29 known variants.
Results: Of the total 158 ALK fusion positive samples,
133 samples harbored echinoderm microtubule-
associated protein-like 4 ALK (EML4-ALK) fusion, 4 samples
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fusion, 4 samples harbored huntingtin interacting pro-
tein 1 ALK (HIP1-ALK) fusion, 1 sample harbored kinesin
light chain 1 ALK (KLC1-ALK) fusion, and the remaining
16 samples harbored novel fusion variants. Of the 133
EML4-ALK positive samples, 55 samples harbored
E13:A20 variants (Variant 1), 55 samples harbored
E6:A20 (Variant 3), 16 samples harbored E20:A20
(Variant 2), 4 samples harbored E18:A20 and 3 samples
harbored E2:A20.
Conclusion: This is the largest molecular epidemio-
logical study to describe ALK fusion variants in East
Asian LUAC patients. EML4 is the most common fusion
partner of ALK gene. About 84% of ALK fusion positive
patients harbor EML4-ALK, and 5.7% harbor non-
EML4-ALK fusions. The remaining 10% harbor fusions
with unknown partners. For EML4-ALK, E13:A20 and
E6:A20 are the most common variants, comprising
more than 80% of EML4-ALK fusion. E20:A20, E18:A20
and E2:A20 are also identiﬁed in East Asian patients.
The constitution of EML4-ALK fusion variants is similar
to the previous reports of patient cohorts in western
countries. All the ALK fusion variants mentioned
should be included in the LUAC fusion screening
assays.
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The hyperglycolytic, hypermetabolic activity of cancer
cells contributes to a ‘stressful’ local tumor environ-
ment in which cells compete for limited nutrients while
being bathed in excessive metabolic waste, including
high levels of lactic acid. Cells within a tumor undergo a
period of environmental stress that is most pronounced
when the growing tumor cell mass exceeds its vascu-
lature, further limiting nutrients and increasing the
accumulation of waste. This can be viewed as a selec-
tion step in which only those cells, both cancer and
stroma, that are best adapted to survive the stress
maintain the ability to proliferate. The aim of this study
was to characterize the molecular basis for the survival
of non-small cell lung cancer (NSCLC) cells when
exposed to environmental stress. To accomplish this
objective we used an in vitro culture system designed
to recapitulate the environmental stressed conditions
of depleted nutrients and accumulated waste experi-
enced by cells within tumors. In examining a panel ofhuman NSCLC cell lines, we unexpectedly found that the
status of RAS was a more important determinant for
surviving environmental stress than the status of p53.
Lines with activating RAS mutations (KRAS or NRAS)
were better poised to survive severe environmental
stress, independent of p53 status. In detailed molecular
cell biological studies comparing a NSCLC cell line wild
type for p53 with an activating KRAS mutation to a
NSCLC cell line mutant for p53 without an activating
RAS mutation, we found that survival correlated with
the level of autophagy in the unstressed cells. Cells that
survived stress had low basal levels of autophagy that
increased upon stress, whereas those that did not sur-
vive stress had elevated autophagy in the absence of
stress that was increased further with the stress. Basal
activation of AKT (also known as Protein kinase B) was
higher in unstressed KRAS cells than in p53 mutant
cells. Active AKT inhibits autophagy, thereby likely
explaining the lower basal level of autophagy in KRAS
mutant cells. In quantitative ﬂuorescence microscopy
studies of living cells, we demonstrated that p53
mutant NSCLC cells, in addition to having elevated
autophagy, have more acidic and motile lysosomes,
phenotypes correlated with increased lysosomal activ-
ity. This basal ‘lysosomal activation’ is likely linked to
the elevation of basal autophagy. Based on these studies
we conclude that the ability of cells to maintain low
autophagy in the absence of stress and to activate
autophagy in response to stress are important for
enhanced survival when cells are challenged with
environmental stress. Activated RAS, via regulation of
nutrient absorption pathways, might make cells less
dependent on stress-activated mechanisms, such as
autophagy, to fulﬁll nutrient needs. Furthermore, loss of
p53 in the absence of KRAS activation results in an
increased basal autophagy, which when further
increased by environmental stress, results in decreased
cell survival. These data suggest that the role of auto-
phagy in cancer cell survival in the context of envi-
ronmental stress is linked to speciﬁc oncogenic
mutations. This ﬁnding has signiﬁcant implications for
targeting autophagy in the treatment of lung cancer.Unique roles for Akt isoforms in
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Lung cancer is the leading cause of cancer-related mor-
talities worldwide and 5 year survival rates are typically
<20%. As traditional therapies are largely ineffective
